ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Lin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0503-9727; OpenAlex author ID A5100403135. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yehan Zhang · 1 shared paper, 2026 · strength 0.23
- Paper KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. DOI 10.1016/j.ccell.2026.10.003 ↗
Zhongjun Wu · 1 shared paper, 2026 · strength 0.23
- Paper KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. DOI 10.1016/j.ccell.2026.10.003 ↗
Dong Gao · 1 shared paper, 2026 · strength 0.23
- Paper KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. DOI 10.1016/j.ccell.2026.10.003 ↗
Gang Jin · 1 shared paper, 2026 · strength 0.23
- Paper KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. DOI 10.1016/j.ccell.2026.10.003 ↗
Weimin Zhang · 1 shared paper, 2011 · strength 0.04
- Paper Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. DOI 10.3892/etm.2011.293 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.